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Abstract
Hypogalactia has a relative high frequency in women having
delivered preterm infants, who often have difficulties in maintaining
a sufficient production of milk for their infants’ needs over prolonged
periods of time. Recent studies have shown a potential galactogogue
effect of silymarin on milk production in animal models (cows and
rats) and in humans (mothers of term newborns); nonetheless, none
of the studies conducted on humans consisted of double-blind ran-
domized clinical trials and no data are available concerning mothers
who delivered preterm infants. The aim of our study was to assess
the efficacy of silymarin (BIO-C®) as galactogogue and its tolerabil-
ity in mothers who delivered preterm infants. We enrolled 50 moth-
ers at 10±1 days post-partum who had delivered infants at <32
weeks’ gestation. They were randomly assigned to receive sachets
indistinguishable for taste and formulation, containing silymarin or
placebo. The mothers were asked to write down the amount of milk
they had produced for each extraction using a breast pump or weigh-
ing the baby before and after the breastfeeding. No differences
emerged in milk production profile between the silymarin BIO-C®
and placebo arms. No adverse events were observed in the 2 arms
among mothers and infants, and silymarin and its metabolites were
not detectable in the analyzed human milk samples. Further investi-
gation on specific patient groups affected by hypogalactia, defined
according to stricter criteria, should be planned to assess the efficacy
of the product in increasing milk production.
Introduction
Breast milk is currently considered to be the optimal form of
enteral nutrition for term and preterm infants until up to six months
postnatal age.1
Mothers of preterm neonates have difficulty in maintaining suf-
ficient volume of human milk for their infants’ needs over prolonged
periods of time.2 Anxiety, fatigue and emotional stress, illness of the
mother or of the baby, incorrect breast attachment or inadequate
breast milk emptying during manual or mechanical extraction3,4
could be inhibitors of lactation, despite appropriate lactation coun-
seling and the use of non-pharmacologic strategies.
When other non-pharmacological measures do not produce an
increase in milk volume, galactogogues can be recommended.
Galactogogues are medications or other substances believed to
assist initiation, maintenance or augmentation of maternal milk
production.5
Domperidone is a medication used like galactogogue and two
studies suggest modest improvements in short-term expressed
breastmilk volumes when a medication is used after insufficient
expressed breastmilk occurs in mothers following preterm delivery.6,7
A possible alternative can be represented by natural products. The
mechanisms of action for most herbals are unknown and most of
them have not been scientifically evaluated.5 Some herbs mentioned
as galactogogues include fenugreek, galega and milk thistle
(Silybum marianum).8
Silymarin is an extract, characterized by the presence of a
flavonolignans fraction (a mixture of silybin, silycristine and silydi-
anin), obtained from Silybum marianum.4 This is a well-known med-
ical plant whose standardized extract is often used in phytotherapy
and in allopathic medicine mainly as a liver protective agent.9
Studies have shown a potential galactogogue effect of silymarin
in milk production in animal models (cows and rats).10-12 Di Pierro
conducted a single-blind randomized clinical trial, and demonstrated
that silymarin BIO-C® significantly increases milk produced by
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mothers of term newborns. This study stated a good tolerability of the
product as well as lack of passage in women’s milk.13
The aim of our study was to assess silymarin BIO-C® efficacy as
galactogogue, its tolerability and its pharmacodynamics in mothers who
delivered preterm babies, by a double-blind randomized clinical trial.
Materials and MethodsSetting and population
This study was conducted at the Neonatal Intensive Care Unit of
the Department of Public Health and Pediatric, University of Turin,
Italy between 2011 and 2012. The protocol of the study was approved by
the Ethics Committee of the Italian Association of Human Milk Banks
(AIBLUD). The target population consisted of women who had deliv-
ered infants at <32 weeks’ gestation and gave written informed con-
sent to participate in the study. Women were considered ineligible if
smokers and if they could not breastfeed because of their clinical con-
ditions, such as HIV infection.Study design
Eligible and consenting women were randomly assigned by using a
computer-based code. The manufacturer of BIO-C® prepared two boxes
of sachets indistinguishable for taste and formulation; one of this con-
tained silymarin in the form of BIO-C® (corresponding to a daily dose:
Cardus Marianus L. dry extract 420 mg, micronized silymarin 252 mg),
the other one a placebo (maltodextrin). Before packaging, the active
drug was micronized, a procedure that improves its oral bioavailability.
Mothers were enrolled in the study 10±1 days post-partum. The posol-
ogy was one sachet every 12 hours for 28 days; the dose was decided on
the basis of the current clinical practice.
After randomization, participants received their drug or placebo
supply for the first 7 days, together with instructions for self-adminis-
tration. The sachets were supplied to the mothers every 7 days (for a
total 28 days) to check the proper intake and to evaluate the compliance
to the study protocol.
Baseline measurements were taken and recorded after randomiza-
tion (day 0). Mothers were asked to express their milk according to the
standard neonatal intensive care unit (NICU) practice: they extracted
their milk at least 6 times per day by Medela Simphony breast pump
(given to the mothers after the discharge; Medela Inc., McHenry, IL,
USA); they stopped the milk extraction one minute after the leaking of
the last drop of milk or, if there was no milk, after 5-10 minutes. If the
baby could suck, the amount of milk was measured weighing the baby
before and after the breastfeeding using an electronic scale, given to
the mother after the discharge (precision ±1 g, mod. Baby One; La
Precisa, Turin, Italy). Qualified staff supported each mother in breast-
feeding, giving them written recommendation and practical support,
focusing on frequency and duration of the extraction, on the use of the
electric breast pump (not used on both breast simultaneously) and giv-
ing advice on diet.
Dedicated recording forms were given to the mothers, who had to
write down the amount of milk they had produced for each extraction,
from both breasts, using the breast pump or weighing the baby before
and after the breastfeeding. In both arms daily milk volumes were cal-
culated at day 0 (that is, the amount of milk produced in the 24 hours
before the start of administration of the sachets), every day in the first
week and at study days 14, 21, 26, 27 and 28 (end of treatment).
The volume of milk extracted was also recorded at day 36 and 43,
whereupon it was also verified that mothers did not take any medica-
tion to increase lactation.
To evaluate the excretion of silymarin in human milk, a milk
sample for each mother was analyzed at study day 14 by an external
laboratory.
Mothers were also asked to record any personal feedback about the
substance they were taking at study day 7, 14, 21 and 28 and to report
any side effect.Aim and study end-points
The purpose of the study was to assess the silymarin galactogogue
action in human milk production. The primary endpoint was the differ-
ence between the mean milk production after 26, 27 and 28 days of
administration and basal production. The secondary endpoints includ-
ed: i) the variation in milk production with respect to the baseline,
after 1, 2, 3, 4, 5, 6, 7, 14, 21 days of administration; ii) the variation in
milk production with respect to the baseline after 8 and 15 days after
the end of administration (36th and 43th day, respectively); iii) occur-
rence of side effects; iv) silymarin excretion in human milk; v) subjec-
tive perception of substance efficacy.Study size
According to Fewtrell and colleagues,9 the standard deviation (SD)
of the mean milk production in the second week after a preterm deliv-
ery is about 160 g/day, whereas is about 280 g/day after one month
since a term delivery. We considered a 150 g/day difference in milk pro-
duction variation between silymarin and placebo, after 28 days of treat-
ment, as the minimum clinically important effect. If we set to a=0.05
(one-tail test) the type I error risk and to (1-b)=0.80 the power of the
study, and assume that the variation in milk production has SD=200
g/day, we find that the required study size is 23 subjects per arm. In the
period February 2011-October 2012 we enrolled 50 women who were
randomized 1:1 to silymarin or placebo.Statistical methods
As for the primary endpoint, Student’s t test for independent sam-
ples was used to test the between-treatment difference of variation in
milk production between day 0 and days from 26 to 28.
As for secondary endpoints, daily milk production profile was fitted
with a mixed linear model including arm (silymarin or placebo), sub-
ject within arm, time and interaction arm×time as covariates.
Assumption of 1st order autoregressive heterogeneous covariance
matrix between the observations of response profile was made. The lin-
ear and quadratic components of milk production profile and their
interactions with arm were evaluated.
To investigate the subjective perception of substance efficacy,
women were divided in two groups on the basis of their guess on the
28th day about the substance they were taking: the group of silymarin-
guess and the group of placebo-guess. Student’s t test for independent
samples was used to test, between guess groups, the difference of vari-
ation in milk production between day 0 and days from 26 to 28.
The analyses were carried out using PROC TTEST, GLM, SGPLOT
and MIXED of SAS software, version 9.4 of the SAS System (SAS
Institute Inc., Cary, NC, USA).Silymarin excretion in human milk: analytical method
Milk samples were extracted in methanol in an ultrasonic bath.
The solution was then centrifuged, filtered at 0.45 mm and analysed by
high performance liquid chromatography coupled to an ultraviolet-vis-
ible spectrophotometry detector and using adequate silymarin standard
solutions as analytical control. The total silymarin content in the sam-
ple (expressed as percentage) is computed by comparison with the
analytical control adding the peaks corresponding to the identified sily-
marin metabolites (silychristin, silydianin, silibyn A, silibyn B, isosily-
bin A and isosilybin B).
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Results
Maternal and infant characteristics at baseline in the silymarin
and placebo arms are shown in Tables 1 and 2. The frequency of multi-
parae was higher in sylimarin arm, as well as the duration of breast-
feeding in women that had breastfed previously.
Two women in the silymarin arm withdrew from the study at day 4
and 7 for use of formula milk and intercurrent disease respectively, and
two women in the placebo arm at day 14 for critical condition of
neonates.
Maternal age, hypertension, parity, multiple pregnancy, diabetes
and gestational age showed no important effect on the primary end-
point (P>0.3 for all effects).
Figure 1 shows average milk production and 95% confidence inter-
vals in the two arms from baseline to the 43rd day. The higher milk pro-
duction observed in the silymarin arm at the baseline (day 0) persisted
up to the 43rd day. Negligible differences in milk production variation
between baseline and the mean of days 26-28 (primary endpoint) was
observed between the two arms (sylimarin: 24.9±38.1 g/day; placebo:
77.3±24.9; difference sylimarin-placebo: -52.4±45.5 g/day, P=0.872).
Figure 2 shows average milk production profiles with their 95%
confidence intervals (CI) estimated with the mixed linear model. No
difference in milk production profile emerges between silymarin and
placebo arms, as indicated by the lack of interaction arm×time in its
linear and quadratic components (P=0.332 and P=0.254, respectively).
Both arms show a sharp irregular variation in milk production in the
first week after enrollment followed by a slow decrease (quadratic com-
ponent: P<0.001).
On day 28th, 17 women believed they were taking silymarin (sily-
marin-guess group: 8 of silymarin-arm, 7 of placebo-arm), 28 women
believed they were taking placebo (placebo-guess group: 14 of silymarin
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Table 1. Maternal characteristics at randomization.
                                                   Arm
                                                    Silymarin(n=25)   Placebo(n=25)
Median age (year)                                           35 (24-42)                    33 (26-56)
Italian nationality (n)                                             23                                   20
Qualification (n)                                                                                              
Middle school                                                        4                                     3
High school                                                           16                                   14
University degree                                                 5                                     8
Diabetes (n)                                                             1                                     2
Hypertension (n)                                                     9                                    13
Other chronic disease (n)                                    9                                     3
Multiparae (n)                                                         10                                    5
Months breastfeeding at last pregnancy
(mean±SE g/day)                                              11.8±2.3                        6.6±1.8
Cesarean delivery (n)                                            19                                   19
Drugs in pregnancy (n)                                         24                                   25
SE, standard error. None of the 50 women had immunization. Values in parenthesis represent range.
Table 2. Infant characteristics at randomization.
                                                   Arm
                                                    Silymarin(n=31)   Placebo(n=31)
Median gestational age (week)                   29 (24-31)                    29 (25-31)
Birth weight (mean±SE), g                            1105±67                       1050±50
Twins (n)                                                                  12                                   12
FGR (n)                                                                     12                                   13
Gender, male (n)                                                    17                                   19
RDS (n)                                                                     30                                   29
PDA (n)                                                                     14                                    7
IVH > grade 2 (n)                                                    1                                     1
Feeding intolerance (n)                                         6                                     5
SE, standard error; FGR, fetal growth restriction; RDS, respiratory distress syndrome; PDA, patent duc-
tus arteriosus; IVH, intraventricular hemorrhage. None of the 62 neonates had necrotising enterocoli-
tis. Values in parenthesis represent range.
Figure 1. Average milk production (g/day) and 95% confidence
intervals in silymarin (grey squares) and placebo (black dots) arm.
Figure 2. Average profile of milk production (g/day) and 95%
confidence intervals in silymarin (grey squares) and placebo
(black dots) arm. Individual profiles were fitted with a mixed lin-
ear model.
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arm, 14 of placebo arm), whereas one did not say her guess. Figure 3
shows average milk production and 95% CI of milk production in the
two-guess groups from baseline to the 43rd day. As expected, women who
believe they were taking silymarin were those with higher milk produc-
tion, but this difference was observed already at baseline. Negligible dif-
ferences in milk production variation between baseline and the mean of
days 26-28 was observed between the two guess-groups [silymarin-
guess: 61.6±35.7 g/day; placebo-guess: 30.9±19.6 g/day; difference (sily-
marin-guess)-(placebo-guess): +30.7±48.4 g/day, P=0.529].
No important adverse events were reported for both mothers and
infants.
Silymarin concentration in human milk was not detectable (<0.3
mg/kg) at day 14 in any of the samples analyzed.
Discussion
Neonatal intensive care unit is a common area of use of the galac-
togogues: the aim is to stimulate initial secretory activation or reduce
the decline of milk secretion in these mothers. Prior to the use of a
galactogogue, the entire feeding process should be thoroughly evaluat-
ed by a lactation expert. Reassurance may be offered, if appropriate.
When intervention is indicated for the dyad, modifiable factors should
be addressed: comfort and relaxation for the mother, frequency and
thoroughness of milk removal, and underlying medical conditions.
Medication should never replace evaluation and counseling on mod-
ifiable factors.5
Because current research on galactogogues is relatively inconclu-
sive and all of the agents have potential side effects, the Academy of
Breastfeeding Medicine (ABM) does not recommend any specific phar-
macological or herbal galactogogues.5 Clinicians should prescribe
galactogogues with appropriate caution with regard to drug-to-herb
interactions as well as to an overall risk-to-benefit approach. Close fol-
low-up of both mother and baby is essential to monitor the status of lac-
tation as well as any adverse events of the drug(s) on mother or infant.5
The herbs were usually recommended as a last resort when other
non-pharmacological measures have not resulted in an increase in
milk volumes.5 A number of botanical remedies (e.g. anise, fennel fenu-
greek seed, nettle and milk thistle) have been traditionally used to
stimulate milk production.4 The available studies on herbs, herbal med-
icines, or herbal galactogogues suffer from the same deficiencies as
the studies for pharmacological agents: small numbers of subjects,
poorly defined eligibility criteria, lack of information regarding breast-
feeding advice, lack of randomization, control and blinding (levels of
evidence II-1,31 II-332).5,14
Four reviews were recently published on the topic of galacto-
gogues. All the reviews analyzed the safety and efficacy of herbal reme-
dies used as galactogogues during lactation. All the studies analyzed in
these reviews enrolled only term mothers at different lactating stages.
All of them concluded that no current recommendation is made for the
use of herbs as galactogogues, and well-designed and well-conducted
clinical trials are needed to generate evidence on this topic.15-18
Recently, the observation that an extract of milk thistle increases
lactation in cows,11 rats12 and women13 has gained renewed interest in
its galacto-genic properties.
In this double blind clinical trial we studied silymarin, an active
ingredient known for many years as a supposed protective liver agent,
due to its possible galactogogue properties. The product was tested and
administered in the form of BIO-C® (420 mg/day). Currently our study
is the first trial focused on mothers who delivered preterm. The present
study was preceded by an investigation aimed at evaluating the tolera-
bility, as well as the total absence of silymarin in milk of women taking
a dose of 420 mg/day in the form of BIO-C®.
Our study does not show a difference, neither in primary nor in
secondary endpoints between the two arms (silymarin vs placebo).
In Di Pierro’s study, women orally treated for 63 days with sily-
marin showed a clear galactogogue role for the product with an
increase of about 86% of the daily milk production (placebo: +32%), but
the eligibility criteria are not clear: gestational age at delivery and age
of neonates are not indicated. In this study the healthy women enrolled
were considered borderline in terms of normal daily milk production.
In our study we included only preterm mothers who had delivered
at gestational age <32 weeks; the assumption was that these women
would present hypogalactia due to breastfeeding difficulties related to
an incomplete lactation process and to higher stress levels. However,
the greatest difficulty that preterm mothers found during breastfeeding
was not only to initiate lactation, but also to maintain an adequate vol-
ume of milk over time. Additionally, a difference in the amount of milk
production at baseline was present (although not statistically signifi-
cant) between the two arms, i.e. women in the silymarin arm were
found to express a higher amount of milk with respect to women in
placebo arm. This finding may be explained by the fact that the sily-
marin arm included a higher percentage of multiparae subjects, with a
history of prolonged breastfeeding duration in previous pregnancies:
actually, preterm mothers with a previous experience of breastfeeding
are reported to produce a higher amount of milk over time.19
No side effect was reported in both groups. Furthermore, silymarin
was not tracked in collected milk samples, which supports the safety of
silymarin both for mothers and neonates. Future studies should there-
fore be performed with a specific focus on mothers affected by real
hypogalactia. However, it is quite difficult to define a cut-off to diag-
nose hypogalactia in quantitative terms, because this condition repre-
sents a variable and dualistic concept that can be better defined as a
quali-quantitative inadequacy to meet the child’s needs over time.
Conclusions
Breastfeeding importance in the first months of life is undeniable,
especially in preterm neonates. However, mothers often need to
increase their milk production and when other non-pharmacological
measures fail, galactogogues can be recommended. Off-label galacto-
Figure 3. Average milk production (g/day) and 95% confidence
intervals in silymarin-guess (grey squares) and placebo-guess
(black dots) groups.
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gogue agents, such as domperidone and metoclopramide, however, can
have serious side effects, which compromise their use.
In this double-blind randomized clinical trial, we investigated the
use of silymarin as a galactogogue for mothers having delivered
preterm infants. No significant difference was found in milk produc-
tion in the period of 26th-28th day of assumption. No side effects were
reported in both groups. Furthermore, silymarin was not found in milk
samples collected.
Further investigation on specific patient groups affected by
hypogalactia, defined according to strict criteria, has to be planned to
assess the efficacy of the product in increasing milk production.
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